A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes.

Trial Profile

A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL-II
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 09 Dec 2017 Results of an analysis comparing the results of the LixiLan and DUAL clinical development programmes, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 08 Dec 2017 Results of post hoc analysis of DUAL-II and DUAL V trials assessing effect of insulin degludec/liraglutide on cardiovascular risk markers presented at the 2017 Congress of the International Diabetes Federation
    • 08 Dec 2017 Results of post hoc analysis of DUAL-I, DUAL-II, DUAL-III, Dual IV and DUAL V trials evaluating the effects of IDegLira in patients with T2D grouped according to their baseline renal function presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top